Objective:
To discuss a novel antiseptic, IRX-101, as a potential alternative to povidone-iodine for intravitreal injections.
Key Findings:
- IRX-101, an aqueous solution of chlorine dioxide, is more effective at killing bacteria than povidone-iodine.
- Patients reported significantly less burning sensation with IRX-101 compared to Betadine.
Interpretation:
IRX-101 shows promise as a more tolerable and effective antiseptic for patients undergoing intravitreal injections.
Limitations:
- Further studies are needed to confirm long-term efficacy and safety.
- Commercial availability and pricing remain uncertain.
Conclusion:
IRX-101 could improve patient experience in IVT prep without compromising infection prevention.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
